Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.49 |
| ▸ | HPGD | P15428 | 9/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | RGS12 | O14924 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14771596 | 1.00 | LMNA (0.50) | LMNATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL14771609 | 0.87 | ALDH1A1 (0.47) | LMNATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL14771613 | 0.87 | ALDH1A1 (0.47) | LMNATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL14771671 | 0.86 | SMN1; SMN2 (0.45) | LMNATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL14771678 | 0.86 | SMN1; SMN2 (0.45) | LMNATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL15823 | 0.85 | LMNA (0.51) | LMNATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL18171976 | 0.81 | HSD17B10 (0.52) | LMNATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL14771649 | 0.81 | HSD17B10 (0.52) | LMNATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL14771674 | 0.81 | ESR1 (0.60) | LMNATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL14771673 | 0.81 | ESR1 (0.60) | LMNATSHRALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2009-10-15 | — | — | US | claimed |
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2008-11-27 | — | — | US | claimed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-20130203602-A1 | SUPPORTED BIOLOGICALLY ACTIVE COMPOUNDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2013-08-08 | — | — | US | disclosed |
| EP-2544664-A1 | SUPPORTED BIOLOGICALLY ACTIVE COMPOUNDS | Danmarks Tekniske Universitet (DK) | 2013-01-16 | — | — | EP | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011110662-A1 | SUPPORTED BIOLOGICALLY ACTIVE COMPOUNDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010078300-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | SLC6A2, SLC18A2, SLC6A3 | LMNA 4559/4885TSHR 1831/4885ALDH1A1 133/4885 |
| US-20130203602-A1 | SUPPORTED BIOLOGICALLY ACTIVE COMPOUNDS | MIF, BMP2, BMP4 | LMNA 911/4885TSHR 4097/4885ALDH1A1 2373/4885 |
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | SLC18A2, SLC18A1, SLC6A2 | LMNA 4054/4885TSHR 1736/4885ALDH1A1 182/4885 |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | SLC6A6, SLC10A2, CLK2 | LMNA 2694/4885TSHR 3455/4885ALDH1A1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.